Mesned Pharma Consult Center’s Post

ArabMed-CRO: Advancing Clinical Research, Amplifying Impact. (Formerly Mesned-CRO) Follow our Page for the latest updates

The Top Players in Clinical Research: A Review of the Leading Companies https://lnkd.in/gPkEiPEN #ClinicalResearch #TopPlayers #LeadingCompanies #ResearchIndustry #HealthcareLeaders #InnovationInHealthcare #MedicalResearch #HealthcareTechnology

🤔 How can predictive models transform clinical trials? As we embrace the era of #digitaltransformation in #clinicaltrials, the newly published JSCDM article delves into a critical aspect of modern clinical research. The shift towards a risk-based approach in clinical trial conduct has been significant in the past decade. This insightful paper by Sina Djali explores the use of predictive models in clinical trials, emphasizing the need for dynamic monitoring and integrated data. The clinical research operating models are not just about delivering therapeutic solutions efficiently; they're about ensuring safe and ethical treatment for patients and study participants. Read the full article on #JSCDM in our "Digital First" collection ➡️ https://lnkd.in/eG2X9Ydv #SCDM Claudine Moore

Interestingly, the terms ‘real-world data (RWD)’ and ‘real-world evidence (RWE)’ are not included in the glossary....

In the BEAMER project, we are partnering with Takeda, Pfizer, Uniklinik Köln, Tilburg University, Centre for Research & Technology Hellas (CERTH), FIB HNJS, empirica Communication and Technology Research and many other organizations to find an innovative way to improve adherence to treatment in both clinical research and clinical care through optimized and personalized patient support. But we do a lot more than this! Want to know how our Patient Feasibility Services can help you to achieve optimal patient experience and better efficacy and efficiency for your clinical trials? Contact Alexandra Sheren (Americas), Simon Klaasen (Europe &ROW), or Ola Hasselgren (Nordics) to learn more and discuss your specific situation and requirements. Let us know what you think and 𝗳𝗼𝗹𝗹𝗼𝘄 𝘂𝘀. #patientadherence #patientengagement #patientrecruitment #clinicaltrials #clinicaloperations #healthcareinnovations #healthcareprofessionals #patientoutcomes #patientcentricity #clinicalcare #patientexperience #healthjourney #patientjourney #patientparticipation #regulators #valuebasedpricing #valuebasedhealthcare #patientsupport

This competitiveness check highlights that the current #EUPharmaLegislation proposal is expected to accelerate a decline in Pharma R&D investment. Some of the details of the report particularly struck me:  - Europe’s share of global R&D investment could fall by a third by 2040, representing €2 billion in lost investments each year. - Germany (followed by Belgium and France) is estimated to be hit hardest, with around €626 million of annual R&D revenues to be lost. Ultimately, patients will bear the brunt of these setbacks. The challenge for the coming decades is not if medical innovation will happen but rather where it will happen and how patients in Europe can benefit from innovative drugs. As a company with strong ties to Europe and substantial contributions to European R&D, Bayer is committed to working with all stakeholders to strive for a patient-focused, competitive pharmaceutical landscape in Europe.

This somehow reminds me of a classical saying from Nobel Prize laureate for economics 2005, Robert Aumann, that economics ultimately is about one word, which is incentives. Similar situation applies to environment topic that it is a topic which should fall into the hands of scientists and economists where the former dedicate to R&D activities for new green technologies and the latter create incentives to ensure economically viable for R&D, for successful market penetration and therefore wide adoption; certainly not into the hands of ideology driven without a clue to advance and to progress. What a pity!

How can real-world evidence (RWE) transform healthcare and clinical trials? Imagine a world where patients effortlessly access their medical records and actively engage in research. Whyze Health is at the forefront of this revolution. Our platform connects all stakeholders, from patients to pharma, using robust RWE to streamline clinical trials and improve decision-making. RWE boosts patient outcomes and promises to transform Ireland's clinical research landscape. Learn how Whyze Health is reshaping the future of healthcare in this enlightening article: https://lnkd.in/eAP2zqVA

Stuart McCully (RWR-Regs) delves into the nuances of the newly-announced FDA and National Institutes of Health draft glossary aimed at establishing consistency in clinical and #RWE research terminology. Read the latest Column at The Evidence Base® #rwd #realworldevidence #realworlddata #pharma #biopharma #regulation #regulatoryaffairs #hta #healthtechnologyassessment #healthdata #healthequity #healthpolicy

The Benefits of Building the Use of Digital Technologies into Clinical Program Design by First Intent Matthew Bonam AstraZeneca Digital technologies have the potential to accelerate the clinical development of new medicines and improve the patient and site experience of participating in a trial. If applied poorly, these same technologies can have the opposite effect. Case studies and patient testimonials will be used to describe the benefits of using digital technologies in clinical programs. Actionable insights will aid clinical teams in the design of digital-first clinical development programs. https://bit.ly/3jRNCin #ScopeSummit #ClinicalTrials